The biopharmaceutical sector recorded 62 layoff rounds in the third quarter of 2025, reflecting a continuation of a challenging employment environment. Major companies including Novo Nordisk, Merck & Co., and Sarepta Therapeutics announced significant workforce cuts as part of cost-saving and strategic pipeline realignment initiatives. These layoffs underscore ongoing industry pressures stemming from pipeline volatility, regulatory scrutiny, and the need to streamline operations amidst changing market conditions.